"Nature's Ozempic" Claims: A Fact Check

“Nature’s Ozempic” is not a scientific term. It is a phrase that sells, and in the last three years it has been attached to berberine, yerba mate, psyllium husk, apple cider vinegar, Akkermansia probiotics, oat water, guava leaf tea, chia seeds and most of the produce aisle.

This article checks the biggest claims one at a time against the actual evidence. Some of them are wholly invented. One or two are more interesting than you might expect. None of them is Ozempic.

First: what does Ozempic actually do, so we have a yardstick?

Semaglutide is a modified version of GLP-1, a hormone your gut releases after you eat. The modifications make it last about a week in the body instead of a couple of minutes. It binds the GLP-1 receptor directly, slows gastric emptying, increases insulin release when blood sugar is high, and acts on appetite centers in the brain.

In STEP 1, a 68-week trial of 1,961 adults published in the New England Journal of Medicine, semaglutide 2.4 mg produced a mean weight change of −14.9% against −2.4% on placebo, an estimated treatment difference of 12.4 percentage points (95% CI −13.4 to −11.5, P<0.001) [22]. In the SURMOUNT-5 head-to-head trial, it produced 13.7%, or 15.0 kg, at 72 weeks; tirzepatide produced 20.2%, or 22.8 kg [1].

That is the yardstick: roughly 33 to 50 pounds, in trials that ran a year and a half, in thousands of people, reviewed by regulators.

Now the claims.

Claim 1: Berberine is “nature’s Ozempic”

Verdict: False, though berberine is not nothing.

Berberine is a plant alkaloid that activates AMPK and changes liver lipid handling. It does not bind the GLP-1 receptor.

A 2020 dose-response meta-analysis of 10 randomized controlled trials found significant reductions in BMI (−0.29 kg/m²) and waist circumference (−2.75 cm), but no significant change in body weight: a weighted mean difference of −0.11 kg with a confidence interval from −0.99 to +0.76 [2]. A 2022 dose-response meta-analysis found −0.84 kg, graded as moderate quality with a “high serious limitation” for risk of bias.

The US Department of Defense’s Operation Supplement Safety program reviewed the same literature and concluded that one review reported a reduction of 0.84 kg, “almost 2 lbs,” in people with certain diseases after up to 18 weeks, but that “when low quality studies are excluded, this reported reduction in weight no longer” holds. Its bottom line: “The evidence does not support claims for berberine as the ‘key to weight loss’” [3].

UCLA Health’s assessment is that the amount of weight you can lose with berberine is unclear and the evidence is inconclusive [4]. The American Academy of Family Physicians published under the headline that the fad “lacks rigorous evidence” and “has potential harms” [5].

Where berberine does have evidence: blood sugar and lipids. A 2008 trial in Metabolism found berberine’s glucose-lowering effect comparable to metformin’s over 13 weeks, and better than metformin on triglycerides and total cholesterol.

Where berberine has risk: it inhibits CYP2D6, CYP3A4 and CYP2C9 and several drug transporters, which can raise blood levels of other medicines you take.

So berberine is a real compound with real metabolic effects. It is roughly 15 to 40 times weaker than semaglutide on the outcome people are buying it for.

Claim 2: Yerba mate is “nature’s Ozempic”

Verdict: Largely unsupported.

Yerba mate found a niche on TikTok, where creators sometimes call it nature’s Ozempic [6].

The mechanism claim traces to a 2011 mouse study by Hussein and colleagues in Biological and Pharmaceutical Bulletin, which reported that mate tea promoted satiety and lowered body weight in mice with GLP-1 involvement [7]. That is a mouse study.

The human study most often cited is a 2001 trial by Andersen and Fogh, which tested “YGD,” a preparation combining yerba mate, guarana and damiana, not mate alone. It found delayed gastric emptying, reduced time to perceived gastric fullness, and weight loss over 45 days in overweight patients [7]. A three-herb blend with two caffeine sources is not the same as the mate product being marketed.

Reported weight effects for mate in human data are typically under two pounds when combined with calorie restriction.

Yerba mate is a pleasant caffeinated tea. That is what the evidence supports.

Claim 3: Apple cider vinegar causes major weight loss

Verdict: The headline study was retracted.

This one is unusually clean-cut.

In March 2024, BMJ Nutrition, Prevention and Health published a randomized, double-blind, placebo-controlled trial of apple cider vinegar in 120 overweight or obese Lebanese adolescents and young adults. Participants taking daily vinegar for 12 weeks reportedly lost about 9% of their body mass. The finding was press-released and generated enormous international coverage [8].

On September 23, 2025, BMJ Group retracted it [9]. The group said complaints and critiques prompted its content integrity team to review the paper and forward it to statistical experts, who found reliability problems. BMJ Group explicitly stated that journalists and others “should no longer reference or use the study findings in future reporting” [9].

NPR covered the retraction, quoting NYU nutrition professor emerita Marion Nestle: “An apple a day may keep the doctor away, but apple cider vinegar as a superfood? If only” [10].

What remains? A 2025 systematic review and meta-analysis of randomized trials in adults with type 2 diabetes or overweight found a pooled standardized mean difference for body weight of −0.39 (95% CI −0.63 to −0.15) [11]. That is a small effect drawn from small trials. Mayo Clinic’s position is that research has not proved apple cider vinegar helps people lose weight, and that experts have not found meaningful weight loss or long-term hunger control with its use [12].

If you like vinegar on your salad, enjoy it. If you bought gummies because of a study, that study no longer exists in the literature.

Claim 4: Psyllium husk is “the new GLP-1”

Verdict: Overstated, but the underlying mechanism is real.

Psyllium is a viscous, gel-forming, poorly fermentable soluble fiber sold as Metamucil and generics. It genuinely does slow gastric emptying and blunt postprandial glucose by increasing gastric viscosity.

Fiber in general does raise gut hormones. Enhanced satiety from soluble fiber involves GLP-1, peptide YY, cholecystokinin and gastric distension, along with slower macronutrient absorption [13].

But two things complicate the “new GLP-1” framing.

First, the weight evidence is modest and mixed. A 2023 comprehensive review and meta-analysis of randomized trials, and a 2025 dose-response meta-analysis of anthropometric indices, both find small and inconsistent effects on body weight, BMI and waist circumference. The effects on LDL cholesterol and glycemic control are much more consistent than the effects on weight [13].

Second, psyllium does not reliably raise GLP-1 at all. In a controlled crossover study of 16 healthy volunteers testing five isoenergetic meals, postprandial GLP-1 concentration was significantly suppressed after a fiber- and protein-rich meal, in contrast to the initial increases seen with other meals, while PYY secretion was prolonged [14]. Poorly fermentable fiber and highly fermentable fiber do different things.

Psyllium is cheap, safe and genuinely useful for fullness, regularity and cholesterol. It is also a bulking fiber, not a hormone drug, and calling it the new GLP-1 sells it short in one direction and oversells it badly in the other.

Claim 5: Akkermansia probiotics are natural GLP-1

Verdict: The most interesting claim in this article, and still much weaker than a drug.

Akkermansia muciniphila is a mucin-degrading gut bacterium. Its P9 protein and the short-chain fatty acid propionate stimulate GLP-1 release from intestinal L cells in mouse and cell studies.

The human evidence is genuinely worth taking seriously, in both directions.

The 2019 proof-of-concept trial (Depommier et al., Nature Medicine, 32 completers, 3 months) found pasteurized A. muciniphila was safe and well tolerated, improved insulin sensitivity by 28.6%, reduced insulinemia by 34.1% and lowered total cholesterol by 8.7%. Body weight fell 2.27 kg versus placebo, but at P=0.091 that was not statistically significant [15].

The 2026 trial (Mount et al., Nature Medicine, published May 12, 2026, NCT05417360) is stronger. Ninety adults completed an 8-week low-energy diet to lose at least 8% of body weight, then spent 24 weeks in maintenance on pasteurized A. muciniphila MucT or placebo. The supplement group regained 1.2 kg against 3.2 kg on placebo (P=0.012) — a difference of about 2 kg — with better preserved insulin sensitivity. Effects appeared largest in people with low baseline Akkermansia and in those with prediabetes [16]. Independent experts called the design sound, randomized, double-blind and placebo-controlled, with a positive primary outcome, while noting that GLP-1 itself and other appetite hormones barely moved in this human study [19].

A caution on the number you will see quoted elsewhere: the trial was funded by the ingredient’s manufacturer, whose press materials rounded the benefit to “about three kilograms.” The published difference is about 2 kg. We use the journal’s figures.

So: a real, well-designed trial showing about 2 kg less regain over six months, in a maintenance setting, after a diet — and notably, one that did not show the GLP-1 rise the marketing rests on.

That is worth knowing. It is also not 15 kg of weight loss, and one industry-adjacent page reviewing the evidence put it plainly: no supplement is a substitute for a prescription GLP-1 medication, and the claim that Akkermansia stimulates a clinically meaningful GLP-1 rise in people is untested.

Best framing: a maintenance and metabolic-health adjunct with the best trial data in its category.

Claim 6: “Oatzempic” and other viral drinks

Verdict: A meal replacement with a clever name.

The oatzempic drink is blended oats, water and lime. There is no trial of it. There is no mechanism connecting it to the GLP-1 receptor.

What it does is straightforward: it is low in calories and reasonably high in fiber, and if you drink it instead of eating a larger meal, you consume fewer calories. That is how any meal replacement works, and meal replacements do help some people. Calling the result “Ozempic” is naming, not pharmacology.

The same logic applies to most viral food-based claims. Fiber and protein increase satiety, satiety reduces intake, reduced intake reduces weight. That chain is real and it is also modest, which is why people who have been eating oatmeal for decades are not at trial-level weight loss.

Claim 7: “GLP-1 patches” deliver GLP-1 through the skin

Verdict: Physically impossible as marketed.

No FDA-approved transdermal GLP-1 product exists. Patches sold on TikTok Shop and elsewhere contain herbal ingredients such as berberine, green tea extract and chromium, not any GLP-1 receptor agonist [6].

There is a hard physical limit here. Intact skin blocks passive absorption of molecules much above roughly 500 daltons. Nicotine patches work because nicotine weighs about 162 daltons. Semaglutide weighs about 4,113 daltons. Even a patch containing real drug could not deliver it through skin in a useful amount.

No randomized controlled trial has shown any over-the-counter weight-loss patch produces meaningful weight loss. In 2007, the FTC settled with Transdermal Products International Marketing Corporation and its owner for $180,000 and banned them from selling weight-loss patches, finding the advertising claims false and unsubstantiated; the order was entered in the Eastern District of Pennsylvania on July 24, 2007, under the FTC’s own headline that products worn or rubbed on the skin do not cause weight loss [20].

Why is this happening at all?

Three forces, stacked.

Demand exceeds affordable supply. GLP-1 drugs are effective, expensive, and often not covered. Self-pay prices in 2026 run $149 to $449 a month. Not everyone can pay that, and a phrase promising the same result for $30 will always find buyers.

The rules are permissive. Under the Dietary Supplement Health and Education Act, supplements are regulated more like food than like drugs. Manufacturers do not need FDA approval before selling. They must notify the FDA that they hold evidence for structure-function claims, but as regulatory counsel at the Center for Science in the Public Interest has pointed out, they do not have to provide that evidence [6].

Enforcement is thin. Regulatory consultants reported in 2025 that the FDA had issued only one warning letter to a supplement company over GLP-1-related claims, a December 10, 2024 letter to Veronvy, which the FDA confirmed in its own December 17, 2024 roundup [17][21]. Over roughly the same period, the agency issued dozens of warning letters to telehealth companies over compounded GLP-1 marketing.

The FTC is the other lever, and its standard is higher than most people realize: in past weight-loss settlements it has required two adequate and well-controlled human clinical studies before a company may make weight-loss claims. Very little in this category meets that.

The number that summarizes the whole category

The Obesity Society screened 20,504 citations, reviewed 1,743 full-text articles, and analyzed 315 randomized controlled trials of 14 purported dietary supplements, therapies or combinations [18].

Only 52 trials (16.5%) were low risk of bias and sufficient to support efficacy. Of those, only 16 showed a significant between-group weight difference, ranging from 0.3 to 4.93 kg [18].

Sixteen out of 315, with a maximum effect of about 11 pounds in the best study in the best category.

An estimated 34% of Americans trying to lose weight have used a weight-loss supplement. That is a lot of people buying into a 5% hit rate.

What is actually worth your money and attention?

If you want a food-and-habit approach that has real physiology behind it: protein and fiber at meals genuinely increase satiety through gut hormone signaling. That is not marketing. It is also a modest effect that works best as part of an overall pattern rather than as a supplement you swallow.

If you are already on a GLP-1 drug: the companion-nutrition category has a defensible rationale. In 2025 the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society published joint nutritional guidance for supporting GLP-1 therapy. Fiber, protein and micronutrient adequacy are real problems when appetite drops 25%.

If cost is why you are here: price the approved options before you spend on supplements. Generic phentermine is about $14 to $41 a month. Generic phentermine/topiramate ER, which produced about 10.9% weight loss in its pivotal trial, is about $59 to $63 a month with a coupon. Contrave can be $20 a month with a copay card or $99 through patient assistance. Foundayo and the Wegovy pill start around $149. A $30 supplement that does nothing is not cheaper than a $15 prescription that does something.

If you want to sanity-check any product: ask whether there is a randomized trial of the finished product, whether the milligram dose on the label matches the study being cited, and whether the outcome reported is actual weight loss or just a biomarker. Those three questions will eliminate almost everything in this category.

This article summarizes what published studies, retraction notices, FDA-approved labeling and regulatory records report. It is not medical advice, and it does not recommend any product, drug or dose. Follow your own prescription and the directions your prescriber and pharmacist give you, and talk to a healthcare provider before starting or stopping anything, including a supplement, especially if you take prescription medications.

Sources

1. Eli Lilly — SURMOUNT-5 complete results published in NEJM: https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy
2. Asbaghi O et al. — Berberine supplementation and obesity indices: dose-response meta-analysis: https://www.sciencedirect.com/science/article/abs/pii/S1744388119303871
3. Operation Supplement Safety (US Department of Defense) — Berberine: the hype for “nature’s Ozempic”: https://www.opss.org/article/berberine-hype-natures-ozempic
4. UCLA Health — What to know about berberine, the so-called “nature’s Ozempic”: https://www.uclahealth.org/news/article/what-know-about-berberine-so-called-natures-ozempic
5. American Academy of Family Physicians — Weight loss fad berberine lacks rigorous evidence, has potential harms: https://www.aafp.org/afp/afp-community-blog/weight-loss-fad-berberine-natures-ozempic-lacks-rigorous-evidence-has-potential-harms
6. PBS NewsHour — In the gray world of GLP-1 supplements online, health experts urge caution: https://www.pbs.org/newshour/health/what-to-know-before-you-buy-a-weight-loss-supplement-on-tiktok
7. The positive effects of yerba maté (Ilex paraguariensis) in obesity — review including Hussein 2011 and Andersen & Fogh 2001: https://pmc.ncbi.nlm.nih.gov/articles/PMC4344557
8. McGill Office for Science and Society — Apple cider vinegar… again: https://www.mcgill.ca/oss/article/health-and-nutrition-pseudoscience/apple-cider-vinegaragain
9. BMJ Group — BMJ Group retracts trial on apple cider vinegar and weight loss: https://bmjgroup.com/bmj-group-retracts-trial-on-apple-cider-vinegar-and-weight-loss
10. NPR — Apple cider vinegar weight loss study retracted: https://www.npr.org/2025/10/05/nx-s1-5562526/apple-cider-vinegar-study-retracted-weight-loss
11. Castagna A et al. 2025 — Effect of apple cider vinegar intake on body composition: systematic review and meta-analysis: https://pmc.ncbi.nlm.nih.gov/articles/PMC12472926
12. Mayo Clinic — Apple cider vinegar for weight loss: https://www.mayoclinic.org/healthy-lifestyle/weight-loss/expert-answers/apple-cider-vinegar-for-weight-loss/faq-20058394
13. Psyllium is a natural nonfermented gel-forming fiber that is effective for weight loss: comprehensive review and meta-analysis: https://pmc.ncbi.nlm.nih.gov/articles/PMC10389520
14. A psyllium fiber-enriched meal strongly attenuates postprandial gastrointestinal peptide release in healthy young adults: https://www.sciencedirect.com/science/article/pii/S0022316622068547
15. Depommier C et al., Nature Medicine 2019 — Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: https://pubmed.ncbi.nlm.nih.gov/31263284
16. Mount S et al., Nature Medicine, published May 12, 2026 — Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial (NCT05417360), doi 10.1038/s41591-026-04394-7. Manufacturer-funded: https://pubmed.ncbi.nlm.nih.gov/42120725
17. SupplySide Supplement Journal — Regulators mostly silent on GLP-1 supplement claims: https://www.supplysidesj.com/supplement-regulations/regulators-mostly-silent-on-glp-1-supplement-claims
18. Batsis JA et al., Obesity 2021 — A systematic review of dietary supplements and alternative therapies for weight loss: https://pubmed.ncbi.nlm.nih.gov/34159755
19. Science Media Centre — Expert reaction to the 2026 Akkermansia weight-maintenance RCT: https://www.sciencemediacentre.org/expert-reaction-to-an-rct-on-the-use-of-pasteurized-akkermansia-muciniphila-muct-for-weight-loss-maintenance-after-an-8-week-low-energy-diet
20. FTC — Weight-Loss Patch Manufacturer Banned From Selling Weight-Loss Patches, Will Pay $180,000 (order entered E.D. Pa., July 24, 2007): https://www.ftc.gov/news-events/news/press-releases/2007/08/weight-loss-patch-manufacturer-banned-selling-weight-loss-patches-will-pay-180000
21. FDA — FDA Roundup: December 17, 2024 (confirms the Veronvy warning letter): https://www.fda.gov/news-events/press-announcements/fda-roundup-december-17-2024
22. Wilding JPH et al., N Engl J Med 2021;384(11):989-1002 — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NCT03548935): https://pubmed.ncbi.nlm.nih.gov/33567185
23. Batsis JA et al., Obesity 2021;29(7):1102-1113 — full abstract record: https://onlinelibrary.wiley.com/doi/10.1002/oby.23110